Submission of Intimation of allotment.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals has allotted 10,74,000 equity shares (face value Rs. 10) at Rs. 20 each (including Rs. 10 premium) to 4 allottees upon conversion of an equal number of warrants. These warrants were originally issued on a preferential basis on 10 January 2025, out of 1,50,00,000 warrants. The company received Rs. 1.61 crore (the remaining 75% of the issue price). Allottees include one promoter (Narahari Belide – 1,00,000 shares) and three non-promoters (Chintalapati Sesha Sai Nikhil – 4,92,000, KS Swetha – 3,82,000, Palakurthi Rakesh – 1,00,000). Post-allotment, paid-up equity capital rose from Rs. 16.14 crore to Rs. 17.21 crore, increasing total shares from 1,61,41,000 to 1,72,15,000.
This is a routine warrant-to-equity conversion that brings in additional capital and modestly expands the share count (around 6.6% dilution). No new public fundraising is involved, but existing shareholders face slight dilution.